HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

CONCLUSIONSHER2 mutations were detected in 3% of patients with lung adenocarcinoma in the LCMC. HER2‐directed therapies should be investigated in this subgroup of patients. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uVJMPY
via IFTTT